Bioorthogonal chemical engineering of rAAV capsid: Advancing gene therapy targeting using proteins

Maia Marchand,Sébastien Depienne,Mohammed Bouzelha,Karine Pavageau,Roxane Peumery,Denis Loquet,Dimitri Alvarez-Dorta,Mickaël Guilbaud,Mikaël Croyal,Aurélien Dupont,Oumeya Adjali,Sébastien G. Gouin,David Deniaud,Mathieu Mével

DOI: https://doi.org/10.26434/chemrxiv-2024-l3f1b

2024-07-29

Abstract:We report the chemical conjugation of recombinant Adeno Associated Virus (rAAV) capsid with various functionalities, including proteins, using a bioorthogonal strategy. rAAVs were azido-coated or DBCO-coated by chemically modifying lysine or tyrosine residues. Lysine residues were modified using a phenyl isothiocyanate anchor, and tyrosine residues using either an aryldiazonium salt or a N-methyl luminol derivative. We demonstrate anchor- dependent labelling levels, as observed with biochemical assays and mass spectrometry. Strain-promoted azide-alkyne cycloaddition (SPAAC) was then implemented and evaluated on the rAAV to append functionalities such as fluorescein, biotin and carbohydrates to the azido- coated capsids. We confirmed the efficiency of the bioorthogonal reaction and observed a stronger reactivity with dibenzylcyclooctyne (DBCO) compared to bicyclononyne (BCN). The optimized SPAAC reaction was finally used to label the viral vectors with two relevant nanobodies targeting specific immune cell receptors (CD62L and CD45). In vitro transduction assays conducted with one rAAV-nanobody conjugate demonstrated the promising targeting properties of these chemically modified vectors. Thus, we anticipate that this strategy will positively impact the field of rAAV capsid engineering and contribute in tissue-specific targeting for the optimisation of gene therapy treatments.

Chemistry

What problem does this paper attempt to address?

The main problem that this paper attempts to solve is to improve the tissue - specific targeting ability of recombinant adeno - associated virus (rAAV) vectors in gene therapy. Specifically, the researchers introduced multiple functional groups, especially proteins, by chemically modifying the rAAV capsid protein to achieve more precise cell or tissue targeting. A bio - orthogonal strategy was adopted in the paper, that is, through the strain - promoted azide - alkyne cycloaddition reaction (SPAAC), small molecules such as fluorescein, biotin, carbohydrates, and nanobodies targeting specific immune cell receptors (such as CD62L and CD45) were covalently linked to rAAV. This strategy aims to overcome the non - target expression and inefficiency problems caused by the broad tissue tropism of existing rAAV vectors, thereby reducing the required vector dose, immunotoxicity and production costs, and ultimately optimizing gene therapy methods.